University of Virginia Patent Foundation

The General Hospital Corporation

Zielbio, Inc.

Kimberly A Kelly

Ralph Weissleder

Nabeel Bardeesy

Siva Sai Krishna Dasa

Alexander L Klibanov

Brent A French

Julien Dimastromatteo

Jill K Slack-Davis

Provided are compositions and methods for use of hornerin-binding molecules, including peptides and antibodies. In some embodiments, the presently disclosed subject matter provides compositions that include horning-binding molecules, including but not limited to peptides, uses for the disclosed compositions, including in methods for treating tumors, methods for increasing the survival of subject with tumor, methods for suppressing tumor growth in subjects, methods for reducing tumor vascularity in subjects, methods for treating diseases, disorders, and/or conditions associated with undesirable hornerin expression; methods for modulating hornerin biological activities, methods for imaging cells, tissues, and/or organs that expresses hornerin, and methods for delivering active agents to cells, tissues, and/or organ that expresses hornerin.

Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells

Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. The disclosure relates, in part, to combinations of therapeutic agents (e.g., anti-plectin-1 antibodies and certain small molecules) that function together (e.g., synergistically) to inhibit cancer cell growth. In some embodiments, the disclosure relates to anti-plectin-1 antibody-drug-conjugates (ADCs).

Plectin-1 binding antibodies and uses thereof

The present invention provides compositions and methods to treat cancer.

Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer

Isolated peptides targeting cardiovascular disease are described herein or one or more conservative amino acid substitutions, deletions or additions of such peptides and methods of use thereof for delivering payloads to specific cell types or tissues.

Target-specific delivery of therapeutic agents

Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. In some embodiments, the disclosure provides anti-plectin-1 antibodies. In some embodiments, the anti-plectin-1 antibodies are conjugated to a targeted moiety (e.g., a therapeutic moiety or a detectable label).

Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying 'accessible' proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.

Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma

The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (&#x3b2;AKTLLPTPGGS(PEG5000))KKKKDOTA&#x3b2;A-NH, to which imaging agents and/or therapeutic agents can be conjugated.

Compositions and methods for detecting plectin-1 as a biomarker for cancer

The present invention provides compositions and methods useful for diagnosing, monitoring the progression, identifying the location, and monitoring the treatment response in ovarian cancer based on detecting and locating VCAM-1 expression.

Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment

The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (&#x3b2;AKTLLPTPGGS(PEG5000))4 KKKKDOTA&#x3b2;A-NH, to which imaging agents and/or therapeutic agents can be conjugated.

Growing community of inventors

Crozet, VA, United States of America

Kimberly A Kelly